Thrombocythaemia Myelofibrosis Treatment Market Report 2025

The thrombocythaemia myelofibrosis treatment market size has grown strongly in recent years. It will grow from $1.6 billion in 2024 to $1.73 billion in 2025 at a compound annual growth rate (CAGR) of 8%. The growth during the historic period is attributed to the increasing prevalence of myeloproliferative disorders, rising awareness of myelofibrosis treatments, the growing geriatric population vulnerable to blood disorders, higher investment in hematology research, and the rising incidence of genetic mutations linked to myeloproliferative disorders.

The thrombocythaemia myelofibrosis treatment market size is expected to see strong growth in the next few years. It will grow to $2.33 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth during the forecast period is driven by the growing adoption of targeted therapies, rising demand for JAK/ACVR1 inhibitors, expanding healthcare infrastructure in emerging markets, an increase in clinical trials for new myelofibrosis drugs, and stronger government support for rare disease treatments. Key trends in the forecast period include progress in personalized medicine, advancements in drug delivery technologies, development of dual-action JAK/ACVR1 inhibitors, innovation in minimally invasive treatment methods, and advancements in combination therapy strategies.

The growing use of digital health technologies is contributing to the expansion of the thrombocythaemia myelofibrosis treatment market. Digital health solutions involve the application of digital tools to improve healthcare delivery, enhance patient outcomes, and support effective health management. Their increasing adoption is driven by the ability to offer remote and accessible healthcare services, which improve patient engagement and overall efficiency of care. In the treatment of thrombocythaemia myelofibrosis, digital health solutions are used to monitor symptoms remotely, track how patients respond to therapy, and support personalized care strategies. For example, in April 2025, the American Hospital Association, a nonprofit organization based in the United States, reported that 86.9 percent of hospitals offered telehealth services in 2022, up from 86 percent in 2021, reflecting consistent growth in digital healthcare adoption. This trend is contributing to the development of the thrombocythaemia myelofibrosis treatment market.

Leading companies in this field are focusing on precision medicine by developing therapies that target specific molecular pathways involved in blood disorders. These include inhibitors that act on Janus Kinase or Activin A Receptor Type 1, which are enzymes that influence abnormal blood cell production. These therapies help reduce symptoms, improve treatment outcomes, and manage anemia more effectively. In September 2023, GlaxoSmithKline, a biopharmaceutical company based in the United Kingdom, received approval from the United States Food and Drug Administration for Ojjaara, also known as momelotinib. This treatment is intended for patients with intermediate or high-risk myelofibrosis. It works by targeting both JAK1 and JAK2, as well as ACVR1, helping to regulate inflammatory pathways and improve hemoglobin levels, reducing reliance on blood transfusions. This approval broadens the available treatment options and addresses anemia, which remains a major challenge in managing the disease.

In July 2022, GlaxoSmithKline acquired Sierra Oncology, a biopharmaceutical company based in the United States, for an undisclosed sum. The goal of this acquisition was to expand GlaxoSmithKline’s presence in the hematology field by adding momelotinib to its oncology portfolio. This drug is specifically developed to treat patients with myelofibrosis who also suffer from anemia, fulfilling an area of high unmet medical need. Sierra Oncology focuses on treatments for rare blood cancers, and the addition of its late-stage therapy strengthens GlaxoSmithKline’s offerings in this specialized area.

Major players in the thrombocythaemia myelofibrosis treatment market are Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, Bristol Myers Squibb Company, GlaxoSmithKline PLC, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Sun Pharmaceutical Industries Ltd., Sumitomo Pharma Oncology Inc., Incyte Corporation, Nippon Shinyaku Co. Ltd., Karyopharm Therapeutics, Celon Pharma S.A., Keros Therapeutics Inc.

North America was the largest region in the thrombocythaemia myelofibrosis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in thrombocythaemia myelofibrosis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the thrombocythaemia myelofibrosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Thrombocythaemia myelofibrosis treatment refers to medical interventions, therapies, and drugs aimed at managing excessive platelet production and bone marrow scarring linked to these blood disorders. The focus is on relieving symptoms, preventing complications, and enhancing patients’ quality of life through targeted and supportive care.

The primary types of thrombocythaemia myelofibrosis treatment include medication, blood transfusion, stem cell transplantation, and others. Medication consists of drugs prescribed to manage symptoms, regulate abnormal blood cell production, lower complications, and improve quality of life. Drug categories include JAK inhibitors, immunomodulatory agents, chemotherapy, and others, administered through routes such as oral, intravenous, and subcutaneous. Distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, specialty pharmacies, and drug stores, while applications span clinics, hospitals, and other care settings.

The thrombocythaemia myelofibrosis treatment market research report is one of a series of new reports that provides thrombocythaemia myelofibrosis treatment market statistics, including the thrombocythaemia myelofibrosis treatment industry global market size, regional shares, competitors with the thrombocythaemia myelofibrosis treatment market share, detailed thrombocythaemia myelofibrosis treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the thrombocythaemia myelofibrosis treatment industry. This thrombocythaemia myelofibrosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The thrombocythaemia myelofibrosis treatment market consists of revenues earned by entities by providing services such as cytoreductive therapy services, supportive and symptom management services, and research services. The market value includes the value of related goods sold by the service provider or included within the service offering. The thrombocythaemia myelofibrosis treatment market also includes sales of ruxolitinib, interferons, blood products, transfusion therapies, and supportive care products. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.